Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors
- 5 August 2016
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (4) , 993-995
Abstract
The hepatitis B virus (HBV) infection is a crucial issue for the management of patients with hematological malignancies, who often receive treatments that suppress the immune system with a conseque...Keywords
This publication has 15 references indexed in Scilit:
- American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug TherapyGastroenterology, 2015
- Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxisAnnals of Hematology, 2011
- Living Donor Liver Transplantation for Acute Hepatic Failure Caused by Reactivation of Hepatitis B Virus Infection After Chemotherapy for Hematologic Malignancy: Case ReportsTransplantation Proceedings, 2010
- Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature reviewInternational Journal of Hematology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Prophylaxis and treatment of hepatitis B in immunocompromised patientsDigestive and Liver Disease, 2007
- Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignanciesBritish Journal of Haematology, 2007
- Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapyHepatology, 2006
- Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatmentLeukemia & Lymphoma, 2006
- Persistent Hepatitis B Virus Infection in Subjects Without Hepatitis B Surface Antigen: Clinically Significant or Purely “Occult”?Hepatology, 2001